Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features
- 31 July 2007
- journal article
- Published by Elsevier BV in The Journal of Molecular Diagnostics
- Vol. 9 (3), 320-326
- https://doi.org/10.2353/jmoldx.2007.060182
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Epidermal Growth Factor ReceptorMutation Testing in the Care of Lung Cancer PatientsClinical Cancer Research, 2006
- Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic FeaturesClinical Cancer Research, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeThe New England Journal of Medicine, 2005
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Mutations of the BRAF gene in human cancerNature, 2002